Skip to content
Outcomes4Me Secures $21M in Funding
Learn more >>
All About Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
All About Cancer
ASCO 2025 Breast Cancer Briefing Room
Cancer Webinars
What We Do
For Patients
For Oncology Care Providers
For Life Sciences
Company
Our Story
Management
Thought Leadership
In the News
Careers
Contact
Sign Up
Get Our App
All About Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
All About Cancer
ASCO 2025 Breast Cancer Briefing Room
Cancer Webinars
What We Do
For Patients
For Oncology Care Providers
For Life Sciences
Company
Our Story
Management
Thought Leadership
In the News
Careers
Contact
Sign Up
Get Our App
Download Outcomes4Me
/
June 4, 2025
Search
ASCO 2025
ASCO 2025: Enhertu remains efficacious regardless of mutation status in HER2-low, ultra-low metastatic breast cancer
Enhertu (fam-trastuzumab deruxtecan-nxki or T-DXd) has shown promising results in slowing down or stopping the...
June 04, 2025
